Quantcast

Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.

Research paper by Marta M Celegato, Dolores D Fregona, Maurizio M Mongiat, Luca L Ronconi, Cinzia C Borghese, Vincenzo V Canzonieri, Naike N Casagrande, Chiara C Nardon, Alfonso A Colombatti, Donatella D Aldinucci

Indexed on: 28 Aug '14Published on: 28 Aug '14Published in: Future medicinal chemistry



Abstract

Recently, novel gold(III)-dithiocarbamato peptidomimetics, designed to target peptide transporters upregulated in several tumor cells have shown promise as anticancer agents.The biological behavior of the most promising derivatives AuD8 and AuD9 was studied in PC3 and DU145 prostate cancer cells. They exert higher cytotoxicity in vitro than the reference drug cisplatin and induce apoptosis, promoting mitochondrial membrane permeabilization and stimulating reactive oxygen species generation. Moreover, they inhibit both selenoenzyme thioredoxin reductase and proteasome activity. Additionally, AuD8 effectively reduces tumor growth in prostate tumor-bearing nude mice with minimal systemic toxicity.Altogether, our results provide insights into the anticancer activity of these gold(III)-dithiocarbamato peptidomimetics and support their potential as new agents for prostate cancer treatment.